Relmada Therapeutics Inc (RLMD)
NASDAQ:RLMD
Total Valuation
Relmada Therapeutics has a market cap or net worth of $733.18M. The enterprise value is $509.11M.
Market Cap$733.18M
Enterprise Value$509.11M
Share Statistics
Relmada Therapeutics has 104,890,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,890,220
Owned by Insiders4.10%
Owned by Institutions37.42%
Financial Efficiency
Relmada Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -67.49%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.61
Return on Invested Capital (ROIC)-67.49%
Return on Capital Employed (ROCE)-0.67
Revenue Per Employee0.00
Profits Per Employee0.00
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relmada Therapeutics is ―. Relmada Therapeutics’s PEG ratio is 0.07.
PE Ratio―
PS Ratio0.00
PB Ratio2.20
Price to Fair Value2.20
Price to FCF-4.16
Price to Operating Cash Flow0.00
PEG Ratio0.07
Income Statement
In the last 12 months, Relmada Therapeutics had revenue of 0.00 and earned -57.39M in profits. Earnings per share was -1.45.
Revenue0.00
Gross Profit0.00
Operating Income-59.10M
Pretax Income-57.39M
Net Income-57.39M
EBITDA-59.10M
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.68
52-Week Price Change2588.46%
50-Day Moving Average4.99
200-Day Moving Average2.92
Relative Strength Index (RSI)65.10
Average Volume (3m)2.58M
Important Dates
Relmada Therapeutics upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Relmada Therapeutics as a current ratio of 14.62, with Debt / Equity ratio of 0.00%
Current Ratio14.62
Quick Ratio14.62
Debt to Market Cap0.00
Net Debt to EBITDA0.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relmada Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Relmada Therapeutics EV to EBITDA ratio is -3.17, with an EV/FCF ratio of -4.09.
EV to Sales0.00
EV to EBITDA-3.17
EV to Free Cash Flow-4.09
EV to Operating Cash Flow-4.09
Balance Sheet
Relmada Therapeutics has $93.01M in cash and marketable securities with $0.00 in debt, giving a net cash position of $93.01M billion.
Cash & Marketable Securities$93.01M
Total Debt$0.00
Net Cash$93.01M
Net Cash Per Share$0.89
Tangible Book Value Per Share$2.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Relmada Therapeutics is $13.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.25
Price Target Upside89.56% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast37.37%